Patent Assignment
Reel/Frame 070837/0034
Assignment of Assignor's Interest
Recorded: 2025-04-14
Pages: 60
Assignor
DICERNA PHARMACEUTICALS, INC.
Executed: 2024-12-30
Assignee
NOVO NORDISK A/S
NOVO ALLÉ, BAGSVAERD, 2880, DENMARK
Covered Properties
(50)
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-Stranded Rna
Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Lipid Delivery Formulations
Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-Stranded Rna
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Application:
13/971,507 →
Publication:
US 2014/0221454
Phase Changing Formulations of Nucleic Acid Payloads
Amine Cationic Lipids and Uses Thereof
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-Stranded Rna
Phase Changing Formulations of Nucleic Acid Payloads
Amine Cationic Lipids and Uses Thereof
Ligand-Modified Double-Stranded Nucleic Acids
Application:
15/621,395 →
Publication:
US 2017/0305956
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-Stranded Rna
Process for Formulating an Anionic Agent
Amine Cationic Lipids and Uses Thereof
Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof
4'-Phosphate Analogs and Oligonucleotides Comprising the Same
Double-Stranded Nucleic Acid Inhibitor Molecules Modified with Tm-Increasing Nucleotides
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-Stranded Rna
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Double-Stranded Nucleic Acid Inhibitor Molecules Containing a Triloop
Application:
17/311,949 →
Publication:
US 2022/0064640
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Methods and Compositions for the Specific Inhibition of Alpha-1 Antitrypsin by Double-Stranded Rna
Patent:
11,312,960 →
Application:
17/400,259 →
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Double-Stranded Nucleic Acid Inhibitor Molecules with Shortened Sense Strands
Methods and Compositions for the Specific Inhibition of Alpha-1 Antitrypsin by Double-Stranded Rna
Chemical Modifications of Small Interfering Rna with Minimal Fluorine Content
Application:
17/766,153 →
Publication:
US 2022/0389430
4'-O-Methylene Phosphonate Nucleic Acids and Analogues Thereof
Application:
17/792,948 →
Publication:
US 2023/0123981
Process for Formulating an Anionic Agent
Application:
17/831,258 →
Publication:
US 2022/0305130
Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Methods and Compositions for the Specific Inhibition of Alpha-1 Antitrypsin by Double-Stranded Rna
4'-Phosphate Analogs and Oligonucleotides Comprising the Same
Systemic Delivery of Oligonucleotides
Application:
18/019,404 →
Publication:
US 2023/0277675
Process for the Backbone Deprotection of Oligonucleotides Containing a Terminal Alkyl Phosphonate Group
Application:
18/723,131 →
Publication:
US 2025/0163097
Methods for Synthesis of Peracetylgalactosamine-1-Pentanoic Acid
Application:
18/860,285 →
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-Stranded Rna
Process for Formulating an Anionic Agent
Related Assignments
(24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 7, 2010
From: BROWN, BOB DALE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 024646/0407 →
Assignment of Assignor's Interest
Jul 22, 2010
From: BROWN, BOB D
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 024726/0479 →
Assignment of Assignor's Interest
Feb 25, 2011
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 025864/0367 →
Assignment of Assignor's Interest
Jan 31, 2013
From: BROWN, BOB D., DR.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 029732/0194 →
Assignment of Assignor's Interest
Jun 19, 2013
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 030645/0213 →
Assignment of Assignor's Interest
Nov 7, 2013
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 031562/0527 →
Assignment of Assignor's Interest
Nov 14, 2013
From: BROWN, BOB DALE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 031602/0707 →
Assignment of Assignor's Interest
Nov 14, 2013
From: BROWN, BOB DALE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 031602/0665 →
Assignment of Assignor's Interest
Mar 12, 2014
From: BROWN, BOB DALE; BASU, SUJIT KUMAR
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 032430/0016 →
Assignment of Assignor's Interest
Nov 25, 2014
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 034264/0969 →
Assignment of Assignor's Interest
Mar 25, 2015
From: FRASER, ALLISTER; SCHWARTZ, DAVID
To: SOLULINK, INC.
Reel/Frame 035247/0017 →
Assignment of Assignor's Interest
Mar 25, 2015
From: SOLULINK, INC.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 035247/0021 →
Assignment of Assignor's Interest
Mar 25, 2015
From: BROWN, BOB DALE; BASU, SUJIT KUMAR
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 035247/0034 →
Assignment of Assignor's Interest
Dec 2, 2015
From: BROWN, BOB DALE; BASU, SUJIT KUMAR
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 037196/0775 →
Assignment of Assignor's Interest
Feb 7, 2017
From: BROWN, BOB DALE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 041192/0611 →
Assignment of Assignor's Interest
Mar 2, 2017
From: BROWN, BOB DALE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 041445/0078 →
Assignment of Assignor's Interest
Mar 2, 2017
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 041445/0110 →
Assignment of Assignor's Interest
May 9, 2017
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 042305/0885 →
Assignment of Assignor's Interest
Jun 5, 2017
From: BROWN, BOB DALE; BASU, SUJIT KUMAR
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 042691/0570 →
Assignment of Assignor's Interest
Jul 24, 2017
From: BROWN, BOB D.; WANG, WEIMAN
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 043075/0102 →
Assignment of Assignor's Interest
Nov 1, 2017
From: BROWN, BOB D.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 044004/0766 →
Assignment of Assignor's Interest
Oct 19, 2018
From: DICERNA PHARMACEUTICALS, INC.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 047238/0085 →
Assignment of Assignor's Interest
Oct 19, 2018
From: BROWN, BOB DALE; YING, BO
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 047238/0031 →
Change of Address
Aug 13, 2020
From: DICERNA PHARMACEUTICALS, INC.
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 053493/0724 →